Propanc Biopharma Appoints Dr. Ralf Brandt to its Scientific Advisory Board

Dr. Brandt to Provide Translational Research Expertise and Clinical
Support Advisory Services

MELBOURNE, Australia–(BUSINESS WIRE)–Propanc
Biopharma, Inc. (OTCQB: PPCB) (“Propanc”), a biopharmaceutical
company developing new cancer treatments for patients suffering from
recurring and metastatic cancer, announced today that the Company has
appointed Dr. Ralf Brandt to its Scientific Advisory Board (SAB). Dr.
Brandt previously served as an Advisory Board member to Propanc over a
seven-year period between 2011 and 2018. During this period, he played
an instrumental role in advancing Propanc’s lead product candidate, PRP,
through early stage and formal preclinical development activities. He is
a co-inventor of Propanc’s lead patent family and a co-author of a peer
reviewed scientific publication, published by Propanc and its research
partners. He will provide significant translational research expertise
and clinical support advisory support services to the company’s drug
development pipeline.

Dr. Brandt previously stepped down from Propanc’s SAB, as he underwent a
merger of his cofounded company, vivoPharm, a global oncology and
immuno-oncology discovery company providing a range of preclinical
services with Cancer Genetics, Inc., a Nasdaq listed company enabling
precision medicine in oncology from bench to bedside. He currently
serves as President of Discovery and Early Development of Cancer
Genetics. During Dr. Brandt’s long career in the pharmaceutical
industry, he has acquired significant knowledge and expertise in leading
business units and representation of services to the preclinical
research market, which includes major global pharmaceutical and biotech
companies from around the world.

“We are pleased to welcome Dr. Brandt back to our Scientific Advisory
Board. He played a pivotal role in advising the company, which enabled
us to complete our preclinical development activities for the
advancement of PRP to a First-In-Human study in cancer patients,” said
James Nathanielsz, Propanc’s Chief Executive Officer. “We look forward
to his continued support and guidance, as we now focus our attention
towards preparing for the planned clinical trial and progressing PRP
through early stage clinical development.”

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (the “Company”) is developing a novel approach
to prevent recurrence and metastasis of solid tumors by using pancreatic
proenzymes that target and eradicate cancer stem cells in patients
suffering from pancreatic, ovarian and colorectal cancers. For more
information, please visit www.propanc.com.

The Company’s novel proenzyme therapy is based on the science that
enzymes stimulate biological reactions in the body, especially enzymes
secreted by the pancreas. These pancreatic enzymes could represent the
body’s primary defense against cancer.

To view the Company’s “Mechanism of Action” video on anti-cancer product
candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video

Forward-Looking Statements

All statements other than statements of historical facts contained in
this press release are “forward-looking statements,” which may often,
but not always, be identified by the use of such words as “may,”
“might,” “will,” “will likely result,” “would,” “should,” “estimate,”
“plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,”
“believe,” “seek,” “continue,” “target” or the negative of such terms or
other similar expressions. These statements involve known and unknown
risks, uncertainties and other factors, which may cause actual results,
performance or achievements to differ materially from those expressed or
implied by such statements. These factors include uncertainties as to
the Company’s ability to continue as a going concern absent new debt or
equity financings; the Company’s current reliance on substantial debt
financing that it is unable to repay in cash; the Company’s ability to
successfully remediate material weaknesses in its internal controls; the
Company’s ability to reach research and development milestones as
planned and within proposed budgets; the Company’s ability to control
costs; the Company’s ability to obtain adequate new financing on
reasonable terms; the Company’s ability to successfully initiate and
complete clinical trials and its ability to successful develop PRP, its
lead product candidate; the Company’s ability to obtain and maintain
patent protection; the Company’s ability to recruit employees and
directors with accounting and finance expertise; the Company’s
dependence on third parties for services; the Company’s dependence on
key executives; the impact of government regulations, including FDA
regulations; the impact of any future litigation; the availability of
capital; changes in economic conditions, competition; and other risks,
including, but not limited to, those described in the Company’s
Registration Statement on Form S-1, filed with the U.S. Securities and
Exchange Commission (the “SEC”) on February 25, 2019, and in the
Company’s other filings and submissions with the SEC. These
forward-looking statements speak only as of the date hereof and the
Company disclaims any obligations to update these statements except as
may be required by law.

Contacts

James Nathanielsz
Propanc Biopharma, Inc.
Investor Relations
[email protected]
+61-03-9882-6723